| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2001;38:280.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Role of nNOS in Regulation of Renal Function in Angiotensin II–Induced Hypertension
k 
ervenka
í Heller
Department of Experimental Medicine, Institute for Clinical and Experimental Medicine (L.., J.M., J.H.), Prague, Czech Republic; Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn (H.J.K.), Bonn, Germany; and Center for Experimental Cardiovascular Research, Department of Physiology, 2nd Medical Faculty Charles University (L..), Prague, Czech Republic.
Correspondence to Ludk ervenka, MD, Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, 1958/9 Víde
ská, CZ-14000 Prague 4, Czech Republic. E-mail luce{at}medicon.cz
Abstract— Previous studies have indicated that in normotensive rats, NO produced by neuronal NO synthase (nNOS) plays an important role in modulating tubuloglomerular feedback (TGF)–mediated afferent arteriolar constriction. It has also been shown that in angiotensin (Ang) II–infused hypertensive rats, there is a reduced ability of nNOS-derived NO to counteract this vasoconstriction. The present study was performed to (1) assess in vivo renal functional responses to intrarenal nNOS inhibition in control and Ang II–infused rats and (2) determine whether changes in renal function following nNOS inhibition are mediated by unopposed stimulation of Ang II receptor subtype 1 (AT1). Wistar rats were infused with either saline (SAL) or Ang II (80 ng/min) by osmotic minipumps implanted subcutaneously. Mean arterial blood pressure of SAL- and Ang II–infused rats on day 13 after implantation averaged 121±4 (n=28) and 151±5 (n=30), respectively (P<0.05). There were no differences in glomerular filtration rate (GFR) (0.68±0.09 versus 0.59±0.09 mL · min-1 · g-1), renal plasma flow (RPF) (2.66±0.31 versus 2.34±0.39 mL · min-1 · g-1), and absolute sodium excretion (0.37±0.07 versus 0.42±0.09 µmol · min-1 · g-1). Intrarenal infusion of SAL did not change GFR, RPF, and sodium excretion in either SAL-infused (n=7) or Ang II–infused rats (n=8). Acute intrarenal administration of the nNOS inhibitor S-methyl-L-thiocitrulline (L-SMTC; 0.3 mg/h) decreased GFR, RPF, and sodium excretion in SAL-infused rats (n=9) by 29±4%, 38±4%, and 70±4% compared with control values (P<0.05). The pretreatment by the AT1 receptor antagonist candesartan (750 ng IR) in SAL-infused rats (n=7) effectively prevented the decrease in RPF (-3±3%) elicited by nNOS inhibition and resulted in an increase in GFR (+25±12, P<0.05) and a concomitant greater increase in sodium excretion (84±12%, P<0.05) compared with control values. In contrast, in Ang II–infused rats (n=10) intrarenal inhibition of nNOS by L-SMTC did not cause significant decreases in GFR, RPF and sodium excretion (-2±2%, -15±10%, and -14±10%, respectively). These results suggest that in normotensive rats nNOS-derived NO counteracts Ang II–mediated vasoconstriction in the pre- and postglomerular microcirculation. Furthermore, Ang II–infused rats exhibit an impaired ability to release NO by nNOS. Decreased nNOS activity is likely to account at least partially for the enhanced TGF responsiveness in Ang II–infused rats and thus may contribute to the maintenance of hypertension in this model.
Key Words: angiotensin II • angiotensin antagonist • nitric oxide • nitric oxide synthase
This article has been cited by other articles:
 |
|
 |
|
  J. Stegbauer, Y. Kuczka, O. Vonend, I. Quack, L. Sellin, A. Patzak, A. Steege, K. Langnaese, and L. C. Rump Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R421 - R428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Patterson, J. J. Mullins, and K. D. Mitchell Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension Am J Physiol Renal Physiol, January 1, 2008; 294(1): F205 - F211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Toda and T. Okamura The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kawada, E. Imai, A. Karber, W. J. Welch, and C. S. Wilcox A Mouse Model of Angiotensin II Slow Pressor Response: Role of Oxidative Stress J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2860 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ichihara, M. Hayashi, Y. Koura, Y. Tada, T. Sugaya, N. Hirota, and T. Saruta Blunted Tubuloglomerular Feedback by Absence of Angiotensin Type 1A Receptor Involves Neuronal NOS Hypertension, December 1, 2002; 40(6): 934 - 939. [Abstract] [Full Text] [PDF]
|
|